Marco Colleoni

20PUBLICATIONS
244CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Psychosocial aspects of childbirth and perinatal mental healthMolecular targetsReproduction
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jan 26, 2026
Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial.

Giampaolo Bianchini, Luca Malorni, Roberta Caputo

|Jan 15, 2026
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study.

Carmine Valenza, Yue Zheng, Monica Milano

|Jul 09, 2025
Breastfeeding After Hormone Receptor-Positive Breast Cancer: Results From the POSITIVE Trial.

Fedro A Peccatori, Samuel M Niman, Ann H Partridge

|Apr 28, 2025
Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA Trial.

Antonio Llombart-Cussac, Catherine Harper-Wynne, Antonia Perelló

|Oct 23, 2024
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP).

Nicholas Turner, Cristina Saura, Philippe Aftimos

Pageof 4